These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10578224)

  • 1. The effect of moxonidine on plasma lipid profile and on LDL subclass distribution.
    Elisaf MS; Petris C; Bairaktari E; Karabina SA; Tzallas C; Tselepis A; Siamopoulos KC
    J Hum Hypertens; 1999 Nov; 13(11):781-5. PubMed ID: 10578224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of moxonidine on lipid subfractions in patients with hypertension.
    Lumb PJ; McMahon Z; Chik G; Wierzbicki AS
    Int J Clin Pract; 2004 May; 58(5):465-8. PubMed ID: 15206502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience.
    Ollivier JP; Christen MO
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S39-48. PubMed ID: 7533226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial.
    Masajtis-Zagajewska A; Majer J; Nowicki M
    Hypertens Res; 2010 Apr; 33(4):348-53. PubMed ID: 20139920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxonidine: a new antiadrenergic antihypertensive agent.
    Prichard BN; Graham BR; Owens CW
    J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective antihypertensive therapy: blood pressure control with moxonidine.
    Prichard BN; Graham BR
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S38-48. PubMed ID: 8872298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of moxonidine in the treatment of hypertension.
    Prichard BN; Graham BR
    J Hypertens Suppl; 1997 Jan; 15(1):S47-55. PubMed ID: 9050986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives.
    Wenzel RR; Spieker L; Qui S; Shaw S; Lüscher TF; Noll G
    Hypertension; 1998 Dec; 32(6):1022-7. PubMed ID: 9856967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly.
    Prichard BN; Graham BR
    Drugs Aging; 2000 Aug; 17(2):133-59. PubMed ID: 10984201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why imidazoline receptor modulator in the treatment of hypertension?
    Schäfer SG; Kaan EC; Christen MO; Löw-Kröger A; Mest HJ; Molderings GJ
    Ann N Y Acad Sci; 1995 Jul; 763():659-72. PubMed ID: 7677385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective imidazoline agonist moxonidine in obese hypertensive patients.
    Sanjuliani AF; de Abreu VG; Francischetti EA
    Int J Clin Pract; 2006 May; 60(5):621-9. PubMed ID: 16700870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug withdrawal and rebound hypertension: differential action of the central antihypertensive drugs moxonidine and clonidine.
    Rupp H; Maisch B; Brilla CG
    Cardiovasc Drugs Ther; 1996 Jun; 10 Suppl 1():251-62. PubMed ID: 8827948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist.
    Ernsberger P; Haxhiu MA; Graff LM; Collins LA; Dreshaj I; Grove DL; Graves ME; Schäfer SG; Christen MO
    Cardiovasc Drugs Ther; 1994 Mar; 8 Suppl 1():27-41. PubMed ID: 8068578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of moxonidine in mild to moderate hypertension.
    Jain S; Malhotra P; Kumari S; Varma S
    J Assoc Physicians India; 2001 Aug; 49():829-30. PubMed ID: 11837474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Negatively charged low-density lipoprotein is associated with atherogenic risk in hypertensive patients.
    Urata J; Ikeda S; Koga S; Nakata T; Yasunaga T; Sonoda K; Koide Y; Ashizawa N; Kohno S; Maemura K
    Heart Vessels; 2012 May; 27(3):235-42. PubMed ID: 21491122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic I(1)-imidazoline agonism : sympathetic mechanisms in hypertension.
    Greenwood JP; Scott EM; Stoker JB; Mary DA
    Hypertension; 2000 Jun; 35(6):1264-9. PubMed ID: 10856275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of moxonidine in elderly patients with resistant hypertension.
    Martin U; Hill C; O' Mahony D
    J Clin Pharm Ther; 2005 Oct; 30(5):433-7. PubMed ID: 16164488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist.
    Kaaja R; Manhem K; Tuomilehto J
    Int J Clin Pract Suppl; 2004 Mar; (139):26-32. PubMed ID: 15117110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.